This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donaldson, S. S. Articles by Weinstein, H. J. Search for Related Content PubMed PubMed Citation Articles by Donaldson, S. S. Articles by Weinstein, H. J. Social Bookmarking                            What's this?

VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin’s Disease: Results of a Prospective Clinical Trial

From Stanford University Medical Center, Stanford, and University of California, San Francisco Medical Center, San Francisco, CA; St Jude Children’s Research Hospital, Memphis, TN; Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston, MA; and Barbara Bush Children’s Hospital at Maine Medical Center, Portland, ME.

Address reprint requests to Sarah S. Donaldson, MD, Department of Radiation Oncology, M/C 5302, Stanford University School of Medicine, Stanford, CA 94305; email: sarah{at}reyes.stanford.edu

PURPOSE: To evaluate outcome and assess toxicity of children and adolescents with early-stage, favorable Hodgkin’s disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and low-dose, involved-field radiation.

PATIENTS AND METHODS: One hundred ten patients with clinical stages I and II, favorable (nonbulky) Hodgkin’s disease were treated with four cycles of VAMP chemotherapy and 15 Gy involved-field radiation for those who achieved a complete response, or 25.5 Gy for those who achieved a partial response to two cycles of VAMP.

RESULTS: With a median follow-up of 5.6 years (range, 1.1 to 10.4 years), the 5-year survival and event-free survival were 99% (lower confidence limit [CL], 97.4%) and 93% (lower CL, 88.6%), respectively. Factors associated with event-free survival of 100% were complete response to two cycles of VAMP and histology other than nodular sclerosing Hodgkin’s disease (NSHD). No serious early or late toxicity has been observed. Patients presenting with clinical stages I and IIA, nonbulky disease involving fewer than three nodal sites have a projected survival and event-free survival of 100% and 97% (lower CL, 93%), respectively, at 5 years.

CONCLUSION: Risk-adapted, combined-modality therapy using only four cycles of VAMP chemotherapy with 15 to 25.5 Gy of involved-field radiation for patients with early-stage/favorable Hodgkin’s disease is highly effective and without demonstrable late effects. These results indicate that pediatric patients with stages I and II favorable Hodgkin’s disease can be cured with limited therapy that does not include an alkylating agent, bleomycin, etoposide, or high-dose, extended-field radiation therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. L. Metzger, S. M. Castellino, M. M. Hudson, S. N. Rai, S. C. Kaste, M. J. Krasin, L. E. Kun, C.-H. Pui, and S. C. Howard Effect of Race on the Outcome of Pediatric Patients With Hodgkin's Lymphoma J. Clin. Oncol., March 10, 2008; 26(8): 1282 - 1288. [Abstract] [Full Text] [PDF]

				S. S. Donaldson, M. P. Link, H. J. Weinstein, S. N. Rai, S. Brain, A. L. Billett, C. A. Hurwitz, M. Krasin, L. E. Kun, K. C. Marcus, et al. Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's Disease J. Clin. Oncol., January 20, 2007; 25(3): 332 - 337. [Abstract] [Full Text] [PDF]

				L. M.L. Chow, P. C. Nathan, D. C. Hodgson, D. Jenkin, S. Weitzman, R. M. Grant, D. Manson, A. Bross, J. J. Doyle, C. Danjoux, et al. Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation J. Clin. Oncol., December 20, 2006; 24(36): 5735 - 5741. [Abstract] [Full Text] [PDF]

				M. L. Metzger, M. M. Hudson, G. W. Somes, R. I. Shorr, C.-S. Li, M. J. Krasin, J. Shelso, C.-H. Pui, and S. C. Howard White Race As a Risk Factor for Hypothyroidism After Treatment for Pediatric Hodgkin's Lymphoma J. Clin. Oncol., April 1, 2006; 24(10): 1516 - 1521. [Abstract] [Full Text] [PDF]

				M. J. Krasin, S. N. Rai, L. E. Kun, T. E. Merchant, M. L. Metzger, S. C. Kaste, S. C. Howard, and M. M. Hudson Patterns of Treatment Failure in Pediatric and Young Adult Patients With Hodgkin's Disease: Local Disease Control With Combined-Modality Therapy J. Clin. Oncol., November 20, 2005; 23(33): 8406 - 8413. [Abstract] [Full Text] [PDF]

				Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540. [Abstract] [Full Text] [PDF]

				M. M. Hudson, M. Krasin, M. P. Link, S. S. Donaldson, C. Billups, T. E. Merchant, L. Kun, A. L. Billet, S. Kaste, N. J. Tarbell, et al. Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease J. Clin. Oncol., November 15, 2004; 22(22): 4541 - 4550. [Abstract] [Full Text] [PDF]

				L. B. Kenney, Y. Yasui, P. D. Inskip, S. Hammond, J. P. Neglia, A. C. Mertens, A. T. Meadows, D. Friedman, L. L. Robison, and L. Diller Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study Ann Intern Med, October 19, 2004; 141(8): 590 - 597. [Abstract] [Full Text] [PDF]

				S. Bhatia, Y. Yasui, L. L. Robison, J. M. Birch, M. K. Bogue, L. Diller, C. DeLaat, F. Fossati-Bellani, E. Morgan, O. Oberlin, et al. High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin's Disease: Report From the Late Effects Study Group J. Clin. Oncol., December 1, 2003; 21(23): 4386 - 4394. [Abstract] [Full Text] [PDF]

				O. Oberlin When Quality of Life Is the Major Challenge J. Clin. Oncol., July 15, 2002; 20(14): 3051 - 3053. [Full Text] [PDF]